[An experience of the use of a fixed atenolol amlodipine combination in real clinical practice: results of multicenter Russian study].
To assess clinical, hemodynamic efficacy and tolerability of a Fixed Atenolol Amlodipine Combination (FAAC) in patients with arterial 1-3 degree arterial hypertension as mono- or combination therapy. Antihypertensive efficacy and tolerability of FAAC was investigated in open noncomparative study in 22 centers in 17 cities of Russia on 570 patients (246 men, 324 women) aged 18-65 years (mean 55,53+8,55 years) with 1-3 degree arterial hypertension. Methods of control included office blood pressure (BP) measurement, 24-hour BP monitoring, electrocardiography, control of biochemical parameters, assessment of efficacy and tolerability. Achivement of target BP level at the background of treatment was noted in 401 patients (70.35%) including 171 (30%) patients on monotherapy with FAAC and 230 (40,35%) patients on combination therapy with FAAC and other antihypertensive drug. After 60 days of monotherapy with FAAC according to data of office measurements systolic BP (SBP) decreased from 161.90+/-14,51 to 129.96+/-8,76 mm Hg (p<0.01), diastolic BP (DBP) decreased from 97.61+/-7.45 to 80.04+/-6.44 mm Hg (<0.01). Significant lowering of heart rate from 79.25+/-9.78 to 65.24+/-7.35 bpm (p<0.01) was also noted. After use of combination of FAAC with other antihypertensive drugs according to data of office measurements SBP decreased from 168.24+/-16,78 to 129.77+/-9.55 mm Hg (p<0.01), DBP decreased from 99.66+/-10.03 to 81.36+/-6.51 mm Hg (<0.01). Heart rate decreased from 80.79+/-10.51 to 66.09+/-8.37 bpm (p<0.01). According to data of 24-hour BP monitoring significant lowering of mean 24-hour, diurnal and nocturnal systolic and diastolic BP as well as of hypertensive burden were also noted. No statistically significant dynamics of laboratory parameters was registered during 60 days of therapy with Tenochek. Tolerability was good in 94% of patients, adverse events with premature withdrawal of the drug took place in 1.4% of patients.